Long-term and age-dependent restoration of visual function in a mouse model of CNGB3-associated achromatopsia following gene therapy

Livia S Carvalho, Jianhua Xu, Rachael A Pearson, Alexander J Smith, James W B Bainbridge, Lynsie M Morris, Steven J Fliesler, Xi-Qin Ding, Robin R Ali

Research output: Contribution to journalArticle

120 Citations (Scopus)

Abstract

Mutations in the CNGB3 gene account for >50% of all known cases of achromatopsia. Although of early onset, its stationary character and the potential for rapid assessment of restoration of retinal function following therapy renders achromatopsia a very attractive candidate for gene therapy. Here we tested the efficacy of an rAAV2/8 vector containing a human cone arrestin promoter and a human CNGB3 cDNA in CNGB3 deficient mice. Following subretinal delivery of the vector, CNGB3 was detected in both M- and S-cones and resulted in increased levels of CNGA3, increased cone density and survival, improved cone outer segment structure and normal subcellular compartmentalization of cone opsins. Therapy also resulted in long-term improvement of retinal function, with restoration of cone ERG amplitudes of up to 90% of wild-type and a significant improvement in visual acuity. Remarkably, successful restoration of cone function was observed even when treatment was initiated at 6 months of age; however, restoration of normal visual acuity was only possible in younger animals (e.g. 2-4 weeks old). This study represents achievement of the most substantial restoration of visual function reported to date in an animal model of achromatopsia using a human gene construct, which has the potential to be utilized in clinical trials.

Original languageEnglish
Pages (from-to)3161-75
Number of pages15
JournalHuman Molecular Genetics
Volume20
Issue number16
DOIs
Publication statusPublished - 15 Aug 2011
Externally publishedYes

Fingerprint Dive into the research topics of 'Long-term and age-dependent restoration of visual function in a mouse model of CNGB3-associated achromatopsia following gene therapy'. Together they form a unique fingerprint.

Cite this